• Independent Data Safety Monitoring Board (DSMB) confirms the acceptable safety profile of Donesta® and recommends to continue the Phase III Clinical Program as planned
  • On track to target marketing authorization in 2023
  • Consolidation of business development strategy of Donesta® by successful major funding transactions in 2020

Liege, Belgium, 16 December 2020 - 7:30 CET - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces that its independent Data and Safety Monitoring Board (DSMB) completed its end-of-year safety assessment of the Phase III Clinical Program of Donesta®, a next generation orally-administered E4-based hormone therapy product candidate for the relief of menopausal vasomotor symptoms (VMS).

Attachments

  • Original document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 16 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 December 2020 06:36:02 UTC